My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

36.23 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 15, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 29, 2021

Gainers Cerevel Therapeutics Hldg (NASDAQ:CERE) shares moved upwards by 42.0% to $17.85 during Tuesday's pre-market session. The company's market cap stands at $2....

Via Benzinga

GeneTx Bio-Ultragenyx's Angelman Syndrome Study To Start Enrollment In Canada ↗

May 19, 2021

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) have received clearance from Health Canada to begin enrolling in the Phase 1/...

Via Benzinga

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin ↗

May 19, 2021

CNS Pharmaceuticals today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM.

Via Talk Markets

Ultragenyx's Gene Therapies For Genetic Metabolic Disorders Show Longer-Term Durable Responses ↗

May 14, 2021

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) has announced longer-term data from the Glycogen Storage Disease Type Ia (GSDIa) and Ornithine Transcarbamylase (...

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

May 06, 2021

Rosenblatt lifted the price target on Qorvo Inc (NASDAQ: QRVO) from $175 to $200. Qorvo shares rose 0.8% to $184.01 in pre-market trading. Needham boosted HubSpot Inc (NASDAQ:...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts ↗

May 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc...

Via Benzinga

The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings ↗

May 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -...

Via Benzinga

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗

May 09, 2021

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...

Via Benzinga

Ultragenyx Pharmaceutical Inc (RARE) Q1 2021 Earnings Call Transcript ↗

May 05, 2021

RARE earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data ↗

May 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Earnings Scheduled For May 4, 2021 ↗

May 04, 2021

Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.